Edition:
India

Aclaris Therapeutics Inc (ACRS.OQ)

ACRS.OQ on NASDAQ Stock Exchange Global Select Market

24.79USD
2:29am IST
Change (% chg)

$-0.05 (-0.20%)
Prev Close
$24.84
Open
$25.00
Day's High
$25.17
Day's Low
$24.50
Volume
127,944
Avg. Vol
108,598
52-wk High
$33.21
52-wk Low
$21.35

Chart for

About

Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and... (more)

Overall

Beta: --
Market Cap(Mil.): $828.20
Shares Outstanding(Mil.): 30.00
Dividend: --
Yield (%): --

Financials

BRIEF-Aclaris Therapeutics wins patent in Japan for treating hair loss

* Aclaris Therapeutics announces the allowance of a U.S. patent application and issuance of a Japanese patent covering tofacitinib for treating hair loss disorders Source text for Eikon: Further company coverage:

24 Oct 2017

BRIEF-Deerfield Mgmt reports 5.90 pct passive stake in Aclaris Therapeutics

* Deerfield Mgmt, L.P. reports 5.90 pct passive stake in Aclaris Therapeutics Inc as of Sept 29 - SEC filing Source text: (http://bit.ly/2wKeWrl) Further company coverage:

10 Oct 2017

BRIEF-Aclaris Therapeutics announces publication of phase 2 trial data of A-101 for treatment of facial seborrheic keratosis

* Aclaris Therapeutics announces publication of data from phase 2 clinical trial of A-101 topical solution for treatment of facial seborrheic keratosis

19 Sep 2017

BRIEF-Aclaris Therapeutics announces issuance of two U.S. Patents covering JAK inhibitors for treating hair loss disorders

* Aclaris Therapeutics announces issuance of two U.S. Patents covering JAK inhibitors for treating hair loss disorders Source text for Eikon: Further company coverage:

05 Sep 2017

BRIEF-Vivo Ventures VII LLC reports 9.5 pct stake in Aclaris Therapeutics

* Vivo Ventures VII LLC reports 9.5 percent stake in Aclaris Therapeutics Inc as of March 15, 2017 - SEC filing

15 Aug 2017

BRIEF-Aclaris announces pricing of public offering of common stock

* Aclaris announces pricing of public offering of common stock

11 Aug 2017

BRIEF-Aclaris Therapeutics posts Q2 loss per share $‍0.56​

* Aclaris Therapeutics reports second quarter 2017 financial results

08 Aug 2017

BRIEF-Aclaris Therapeutics has submitted a marketing authorization application with medicines product agency in Sweden

* Has submitted a marketing authorization application with medicines product agency in Sweden

03 Aug 2017

BRIEF-Aclaris Therapeutics submits investigational new drug application for ATI-50002

* Aclaris Therapeutics submits investigational new drug application for ATI-50002 to treat Alopecia Areata

02 Aug 2017

Earnings vs. Estimates